secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001628280-24-043500
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports up to 80% gene correction in Wilson's Disease; on track for IND-enabling
--------------------------------------------------------------------------------

- GalNAc-LNP delivery of Prime Editors achieved up to 80% precise correction of ATP7B H1069Q mutation in humanized mice.
- In NHPs, up to 51% precise editing of liver cells with surrogate H1069Q Prime Editor; no off-target edits detected.
- IND-enabling activities for Wilson's Disease program to start in 4Q 2024; IND/CTA filing expected 1H 2026.
- GSD1b program data: up to 85% precise liver cell editing in NHPs, durable to 44 weeks, no safety concerns.
- Universal liver-targeted LNP platform shows modularity; can be adapted to other rare and non-rare liver indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/0001628280-24-043500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024043500/prme-20241024.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-043500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer